South Africa has detected 6,375 new Covid-19 cases in the last 24 hours, bringing the total number of laboratory-confirmed cases to 3,921,633.
This increase is 19.5% positive, announced the National Institute of Infectious Diseases (NICD), a division of the National Laboratory Health Service.
Most new cases today are from Gauteng (34%) and then to the Western Cape (23%). KwaZulu-Natal was 14%; The Eastern Cape was 10% and the Free State 7%. The North Cape and the Northwest accounted for 4% each; Mpumalanga accounted for 3% and Limpopo for 1% of today’s cases.
The country also registered 18 deaths, 6 of which occurred in the last 24-48 hours. Thus, to date, the total death toll has reached 100,916 people.
“Due to the ongoing audit conducted by the National Department of Health (NDoH), the number of deaths from Covid-19 may be recorded,” the NICD said.
25,025,578 tests were conducted in both the public and private sectors.
134 people were hospitalized in the last 24 hours.
WHO has authorized the Chinese vaccine CanSinoBIO Covid-19
The World Health Organization on Thursday gave the green light to the Covid-19 vaccine from Chinese manufacturer CanSinoBIO – the ninth blow to receive WHO approval.
The WHO has authorized the emergency use (EUL) of the disposable Convidecia vaccine when China is battling a virus revival caused by the Omicron variant.
This is the third Chinese-made vaccine approved by the UN health agency after Sinovac and Sinopharm.
Convidecia was found to be 64 percent effective against symptomatic disease and 92 percent effective against severe Covid-19, the WHO said.
“The vaccine meets WHO standards for protection against Covid-19 and … the benefits of the vaccine far outweigh the risks,” the UN Health Agency said in a statement.
WHO vaccination experts have recommended it to people over the age of 18.
The WHO stated that Convidecia could be used as a booster dose after completion of the primary series using any other EUL Covid-19 vaccine.
READ ALSO: Special tribunal finds extension of contract for COVID-19 4.8 million rupees illegal
– Traditional vector method –
The injection has already been deployed in several countries, including China, Argentina, Chile, Malaysia, Mexico and Pakistan.
By the end of 2021, more than 58 million people have already been vaccinated, including nearly 14 million in China, the WHO said.
The WHO has now granted EUL status to nine Covid-19 vaccines and their variants: Pfizer / BioNTech, AstraZeneca, Janssen, Moderna, Sinovac, Sinopharm, Bharat Biotech, Novavax and CanSinoBIO.
Convidecia is based on modified human adenoviruses. AstraZeneca and Janssen vaccines are also based on viral vector technology.
A more traditional approach uses a genetically engineered version of the common cold adenovirus as a “vector” to transmit genetic instructions to human cells.
Convidecia “demonstrates a favorable safety profile in people of all ages,” causing strong immune responses to both binding and neutralizing antibodies, the WHO said.
– Approval stamp –
The EUL process examines the quality, safety and efficacy of vaccines and includes an inspection of the production facility.
The WHO says the EUL approval gives countries, funders, purchasing agencies and communities the confidence that the vaccine meets international standards.
The WHO list paves the way for countries to approve and import vaccines for distribution, especially those that do not have their own international standard regulator.
It also opens the door for injections to enter the Covax Global Vaccine Exchange Complex, which aims to ensure equal access to doses around the world, especially in poor countries.
In August, the WHO began reviewing data on the CanSinoBIO vaccine.
Other vaccines are also on the way to a solution to the EUL, with the WHO examining data on another Sinopharm injection, as well as vaccines from French companies Sanofi, Chinese Clover and Zhifei Longcom and Iranian Shifa Pharmed.
The EUL process against Russian Sputnik V has stalled.
Hundreds of vaccine candidates are working in laboratories around the world.
The WHO is aware of 156 that are in clinical development – human trials – and 198 that are in the preclinical phase.
More AFP information